Evolent Health Inc (EVH) reported quarterly earnings results on Thursday, May-12-2016. The company said it had a profit of $-0.16 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.04. Analysts had a consensus of $-0.20. The company posted revenue of $49.50 million in the period, compared to analysts expectations of $47.42 million. The company’s revenue was up 33.8% compared to the same quarter last year.
Many Wall Street Analysts have commented on Evolent Health Inc. FBR Capital Initiated Evolent Health Inc on Mar 29, 2016 to “Outperform”, Price Target of the shares are set at $16.
Evolent Health Inc closed down -0.11 points or -0.94% at $11.64 with 47,976 shares getting traded on Tuesday. Post opening the session at $11.74, the shares hit an intraday low of $11.54 and an intraday high of $11.874 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.
In a different news, on Jun 10, 2015, Gary Piefer (Chief Medical Officer) purchased 2,000 shares at $17.00 per share price.
Evolent Health Inc. is engaged in the healthcare delivery and payment markets. The Company’s platform enables providers to migrate their economic orientation from fee-for-service (FFS) reimbursement to value-based payment models. It provides an end-to-end technology-enabled services platform for providers to transition their organization in value-based payment models. It markets and sells services to providers throughout the United States. The Company works with its partners in two phases. In the transformation phase it works with its partners to develop a plan for their transition to a value-based care model. During the second portion of the transformation phase the Company works with its partner to implement the Blueprint. During the transformation phase the Company seeks to enter into long-term agreements with its partners. In the platform and operations phase the Company establishes a local market presence and embeds its resources alongside the Company’s partners.